Actinium Pharmaceuticals, Inc. [NYSEAMERICAN: ATNM]
Actinium Pharmaceuticals Inc. is a clinical stage biotech focused on improving patient access and outcomes to cellular therapies such as bone marrow transplant (BMT) and CAR-T with its proprietary, chemotherapy free, targeted conditioning technology. Actinium is the only company with a late stage, multi-disease, multi-target, drug development pipeline focused on targeted conditioning. Its targeted conditioning technology is enabled by Antibody Radio-Conjugates (ARC) that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is also developing its proprietary AWE (Antibody Warhead Enabling) technology platform which utilizes radioisotopes coupled with antibodies to target a variety of cancer antigens.
Iomab-B, Actinium's lead product candidate is an anti-CD45 antibody labeled with iodine-131 that is currently enrolling patients in the pivotal Phase 3 SIERRA trial in patients age 55 or older with active, relapsed or refractory AML. Actinium's Iomab-ACT program is an expansion of its CD45 program that is intended to be a universal, chemo-free solution for targeted lymphodepletion prior to CAR-T. The Iomab-ACT program is administered as a single outpatient infusion and is expected to improve CAR-T cell expansion, reduce CAR-T related toxicities and expand patient access to CAR-T treatment and other adoptive cell therapies.
Actinium's pipeline also includes a potentially best-in-class CD33 program with its ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in multiple Phase 2 and Phase 1 clinical trials for targeting conditioning and as a therapeutic in multiple hematological diseases and indications.
Actinium's clinical programs are covered by a portfolio of over 100 patents covering composition of matter, formulations, methods of use, and methods of manufacturing the radioisotope Actinium-225.
A German privately-financed, clinical stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials.
A clinical stage Swedish biotech company with a broad product pipeline focused on developing innovative next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
The company operates a focused experimental medicine model and currently has three clinical stage proprietary programs. The first two are therapeutic programs that targets psoriasis and B-cell driven autoimmune diseases, respectively. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer. In addition to the partnering opportunities to its proprietary pipeline, the company offers the half-life extension technology, Albumod™, for out licensing.
Affibody has ongoing commercial relationships with several companies such as AbClon, Alexion, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, and Swedish Orphan Biovitrum.
Amryt Pharma is a commercial-stage pharmaceutical company focused on acquiring, developing and commercializing innovative new treatments to help improve the lives of patients living with rare and orphan diseases. Founded in August 2015 , Amryt has subsequently made 2 corporate acquisitions, licensed EU/MENA rights to a commercial-stage orphan asset (Lojuxta/lomitapide for the treatment of Homozygous Familial Hypercholesterolemia) and licensed a gene therapy platform technology from University College Dublin. The Company is traded on the London AIM market under the ticker AMYT. The Company remains highly transactional and continues to actively seek to identify assets (in particular commercial or late stage development assets) which present a good strategic fit.
A start-up dedicated to developing treatments for muscle dystrophies and T2D through two complementary, cutting-edge approaches: a) NCE from cell-based in vitro HTS based on stem cell-derived normal and disease in vitro models b) Cell therapy in vivo using stem cell-derived satellite cells or brown adipocytes
Exclusive rights to know-how and patents generated by Prof. Olivier Pourquié (Strasbourg/Harvard) for the high-yield, high-abundance generation of paraxial mesodermal cells in vitro.
Partnership opportunities for pharma companies to develop customized in vitro assays for compound testing (e.g. Boehringer Ingelheim) and develop cell-based therapies. First investors in 2013 (AFM, French Muscular Dystrophy Association) 2015, Cap Innov’Est and Boehringer Ingelheim Venture Fund in 2018. Now seeking new co-investors (8 M€) for 2 programs up to IND in 3 years.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
A biotechnology company developing next-generation immunotherapies via individualisation of therapeutic products to precisely leverage the immune system of each patient.
Due to both the immense complexity of immunity and the significant differences in the composition of the immune system between individuals, there is a need to individualise targeted immunotherapeutics. Anocca’s unique technology platform captures key information from the immune system of each individual to deliver a range of immunotherapies specifically tailored to target the disease attributes of each patient, and to work safely within the constraints of each patient’s immune system.
Anocca’s first clinical programs aim to deliver cellular therapies equipped either with targeting receptors from our receptor libraries that are tailored for defined groups of individuals, or equipped with targeting receptors that are created for each patient in a fully individualised manner.
Ares Genetics (ARES), a Vienna-based digital diagnostics start-up is revolutionizing infectious disease diagnostics and therapeutics by artificial intelligence based DNA testing to improve patient outcomes at reduced costs. To achieve this, ARES makes use of high-resolution next generation sequencing (NGS) technology in combination with a proprietary pathogen and antibiotic resistance reference database, ARESdb for result interpretation.
Founded in March 2017, ARES makes revenue from services as well as IP licensing and its customers and strategic partners include leading anti-infectives manufacturers (e.g. Sandoz), a prime supplier of biological data applications (QIAGEN) as well as one of the world’s largest NGS providers (BGI/MGI). As of September 2019, ARES has entered into a multi-phase partnership with an undisclosed leading global in vitro diagnostics corporation to jointly advance human diagnostic solutions based on ARESdb and the company is currently fundraising to rapidly scale its business in EU and US.
A drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Our approach is “first-in-class” with the potential to halt or even reverse degeneration of the nervous system. We are committed to advancing novel and innovative research, developing products that are affordable and accessible in alignment with our strategy focused on the people that we ultimately aim to serve with our therapies. We are mission-driven to restore lives by advancing bold therapies, thoughtfully and urgently.
Atriva Therapeutics, quantum leap in antiviral therapies: Atriva is the first clinical stage company, successfully targeting host-cell factors. Replication of RNA viruses like Hantavirus, Influenzavirus, Coronaviruses (SARS, MERS), Flaviviruses (Dengue, West-Nile, Zika) depends on the RAF / MEK / ERK signaling cascade. ATRIVA discovered that blocking this pathway effectively impairs viral replication and favorably modulates the immune system of the host (dual mode of action). ATRIVA ATR-002, a selective non-competitive MEK1/2 inhibitor, is first-in-class for tackling influenza, Hantavirus, and influenza-like-illness. Viruses depend on MEK function for their replication and spreading. ATR-002, a small molecule in one-daily oral presentation successfully finished phase 1 clinical study in doses up to 1 g/d. For severe influenza best-in-class benefits are proven in preclinical studies: •Therapeutic activity 4 days after infection against all known influenza strains, •Uniquely beneficial for patients with severe influenza at risk developing serious complications, due to dual mode of action, •Resistance formation hardly possible: virus cannot replace missing cellular function (shown with Baloxavir-resistant virus strain), Lead project ATR-002 is developed for influenza in high-risk patients. ATR-004 is developed for Hantavirus Pulmonary Syndrome (HPS), Hanta Fever Renal Syndrome (HFRS). After preclinical PoC in Q3 2019, Atriva will submit Orphan Drug Designation (ODD) in USA in Q4 2019. ATR-004 is first-in-class for Hantavirus with up to 150,000 cases/y in the Americas, Asia and Europe (fatalities up to 40%, HPS). US-NIH acknowledged these benefits as important breakthrough for pandemic influenza and hantavirus. Atriva has raised € 4.5 Mn seed round in 2017 and made initial closing of € 6 Mn of the series A/B round in early 2019. The series A/B of € 32 Mn total closed by December 2019 shall advance the ATR-002 lead in influenza to confirmatory phase 2b study ) and ATR-004 to initial clinical PoC in 2023.
BioEcho Life Sciences GmbH
BioEcho is a Biotech start-up developing disruptive technologies and products for molecular diagnostics, molecular breeding and genome research.
The company has developed revolutionary single-step technologies for dramatically accelerated and simplified genomic Sample Preparation (DNA and RNA isolation processes). We apply these technologies in the development of more convenient Liquid Biopsy procedures (isolation of circulating nucleic acids), high-throughput automation and Point-of-Care diagnostics applications.
Molecular diagnoses workflows consist of 2 general steps, i) Sample Preparation (DNA/RNA isolation) followed by ii) Sample Analysis. Our technologies will allow to bring genomic Sample Preparation to the performance level required to keep pace with the pacemaker technologies in Sample Analysis, e.g., Next Generation Sequencing, PCR. BioEcho technologies speed up the isolation processes 10-fold, reduce process steps at least 5-fold and improve downstream Sample Analysis performance and robustness by significant increase in DNA quality. Moreover, BioEcho products and processes are sustainable in avoiding toxic materials and by saving of 70% plastics waste.
BioEcho has been founded by an experienced team of experts in the field of genomic Sample Preparation with formerly leading positions at Qiagen and other companies. The organization has 15 employees, is fully digitalized and set up to meet the increasing demand from the market. We are enagaged in deals with major players in the life sciences field. We look for a major investment in order to support our growth plans.
A leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation.
Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process.
The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase II/III clinical development for the treatment of delayed-union fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an enhanced viscosupplement, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis.
Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio as well as knowhow. http://www.bonetherapeutics.com
Boston Pharmaceuticals is a translational drug development company. It was founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D Executive from Eli Lilly. With $600M committed capital from Gurnet Point Capital, Boston Pharma’s business model is focused on partnering and developing therapeutics from late pre-clinical to clinical POC. In the past 3 years, we have built an experienced clinical development team and acquired a diverse portfolio of fifteen programs in oncology, autoimmune, cardiovascular, dermatology, anti-infective, gastrointestinal, and metabolic, including recent deals with GSK, Novartis, and other Pharma and biotech partners. In principle, we are agnostic with regards to indication or molecular modality. During this conference, we are seeking in licensing and out licensing partnering discussions.
A Swedish biotechnology company that specialises in the development of antibodies for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies for treatment of non-small cell lung cancer and pancreatic cancer, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).
CanVirex is a Swiss biotech company developing oncolytic viruses as a multiplexed immune-modulating platform for cancer therapy.
The company is a spin-off from the Heidelberg University Hospital in Germany and participates in the Heidelberg network for clinical development of proprietary virus constructs. CanVirex’s virus constructs are based on 15 years of academic research with a focus on safety, immune modulation and commercialization.
CanVirex implements a translational program that combines clinical testing with scientific research. The translational approach will allow for a personalized therapeutic approach by rational selection of cancer patients.
Cardior Pharmaceuticals GmbH (Cardior) was founded 2016 by Prof. Thomas Thum as a spin-off from Hannover Medical School. A Series A financing round of 15 Mio. € was successfully closed in May 2017 with five international leading venture capital funds including LSP, BioMedPartners, Boehringer Ingelheim Venture Fund, Bristol-Myers Squibb and High-Tech Gründerfonds. The company is dedicated to becoming a world-leader in design, research and development of non-coding RNA based therapeutics and diagnostics for cardiovascular diseases. These non-coding RNAs are a novel class of regulatory RNAs and have huge therapeutic potential. As its lead compound “CDR” Cardior is developing an anti-sense oligonucleotide as therapeutic to inhibit a specific non-coding RNA in the heart controlling cardiac growth, autophagy and contractility. Its inhibition reverses cardiac remodeling, restores normal cardiac function and can revolutionize the treatment of patients with myocardial infarction-induced as well as chronical heart failure. New innovative treatments of heart failure are scarce. But with this novel approach Cardior’s clear advantage is having a well-characterized target with convincing preclinical efficacy and safety data leading to a superior approach for the treatment of patients with heart failure. Within only two years Cardior has advanced from research to clinical stage. The company’s lead compound started a clinical phase 1b trial in June 2019. After proof-of-concept (POC) data and clinical validation Cardior seeks to market its lead compound in collaboration with a big pharma partner. Besides the patent protected lead compound Cardior has access to a large patent portfolio consisting of several candidates for heart failure therapy and other indications, e.g. kidney fibrosis.
Every year more than 50 million people suffer from skin defects and need skin transplantation to restore skin function. Unfortunately, standard of care is often scarce and non effective leaving these patients with scars. Scars are disfiguring but also highly comforting, they can impair growth and movement and require serial surgeries and intense homecare. Often, psych-social rehabilitation too. CUTISS can now offer a solution: personalized, bioengineered skin grafts that can be produced in large quantities from a small biopsy and that due their biological characteristics will minimally scar after transplantation. Burn victim, burn survivors and all patients in need for skin could now finally have an option. Skin though is our largest organ. It takes more than clinical validation (ongoing phase II) to reach out to patients. This is why we are working on the the scale up already and trying to convert the actual manual production process into an automated one. denovoSkin, our first in line product, is envisioned to be the first-in class automatically produces personalized skin tissue therapy: safe, effective and accessible.
Cyxone develops novel drugs to improve quality of life for patients suffering from autoimmune diseases.
Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders.
Cyxone’s technologies have the potential to address an unmet need to develop new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company’s development portfolio comprises Rabeximod in a clinical phase II program for RA and T20K that has successfully completed phase I infusion study. http://cyxone.com/
DCprime focusses on relapse vaccines, a novel class of cancer vaccines aimed at supporting immune control over residual disease, in order to prevent or delay tumour recurrence.
The company is currently testing its lead product DCP-001 in an international Ph II trial in AML. The study focuses on patients in clinical remission but with measurable residual disease (MRD) and who are not eligible for stem cell transplantation, posing a high risk of relapse.
DCprime is developing a broader relapse vaccine pipeline in both haematological cancers and solid tumour indications.
We are a global biotechnology company focused on further improving and leveraging the patented and proprietary C1 expression system to help bring biologic vaccines and drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers to improve access and cost to patients and the healthcare system – but most importantly to save lives.
Founded in mid-2015 and is a privately-owned biopharmaceutical R&D company based in Shanghai with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around oncology and other areas of high value to patients. EpimAb’s frontrunning program, EMB01, is a dual cMet and EGFR inhibitor and is currently being investigated in a Phase I/II trial for treatment of solid tumors. Its differentiated mechanism called co-degradation, enabled EMB01 in preclinical models to prolong tumor regression many days beyond dosing. EpimAb’s pipeline also contains highly innovative immune-oncology assets entering preclinical development, including EMB02, a dual checkpoint inhibitor with a unique efficacy profile in preclinical models, that is expected to enter clinical studies in 2020. Furthermore, EMB06, a T-cell engaging bispecific with a unique safety profile.
EpimAb is diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide. The partnering models range from straightout technology licenses, research collaborations, cross-licenses, co-development as well as outlicensing.
A clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet need. "Small, but tough." That’s the best description of this outstanding Finnish biotech company looking to conquer some of the hardest diseases on the planet, e.g. ARDS, pancreatic cancer, glioblastoma, as well as tuberculosis. The Company currently has a pipeline focusing on vascular damage, leucocyte migration and immunotherapy. Faron’s pipeline is based on endothelial receptors involved in regulation of immune responses. Faron has mastered control of this response in both directions; slowing down immune escalation, and removal of immune suppression.
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx. https://www.gaintherapeutics.com/
Genclis commercializes pre-clinical and cellular models in allergy and autoimmunity to evaluate novel therapeutic, probiotic and nutritional solutions.
Genclis assists commercial partners in:
Evaluating intrinsic allergenicity of pharmaceutical, food and cosmetic ingredients;
Etablishing industrial procedures to control or suppress ingredient’s allergenicity;
Genclis engages in exclusive industrial partnerships for co-development of Transcription Infidelity Assisted Sequential Immunization programs for infectious and immune diseases. Genclis manufactures and commercializes cutting edge reagents for diagnostic and preclinical use.
GeNeuro’s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis (MS) and type 1 diabetes (T1D) by neutralizing potential causal factors expressed by human endogenous retroviruses (HERV), which represent 8% of the human DNA. This new approach focused on HERVs is based on more than 25 years of R&D, including 15 within Institut Mérieux and INSERM before the creation of GeNeuro in 2006.
GeNeuro's lead drug candidate, temelimab, is a humanized monoclonal antibody targeting the pathogenic protein HERV-W Env to block key neurodegenerative mechanisms of multiple sclerosis, through reducing microglial activation and through the rescue of the myelin repair process, independently of the immune pathways used by existing drugs. GeNeuro’s recent Phase IIb and its extension have shown its impact on key neuroprotection markers known to be linked to disease progression. These results confirm the potential of temelimab to act against disease progression, the largest unmet medical need in MS. This is also the first time that the benefit of a treatment targeting endogenous retrovirus protein has been observed in a clinical trial, opening a field led by GeNeuro to tackle other areas of unmet medical needs such as T1D or amyotrophic lateral sclerosis.
GlyCardial Diagnostics is focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event. The quantification of circulating ApoJ-Glyc levels as a biomarker of ischemia will represent a clinical advantage compared to the available methodologies as it would: allow the early diagnosis of an ischemic event in the absence of the irreversible necrosis of the tissue; speed up the triage of patients with acute chest pain; and improve the risk stratification and prognosis of patients with ischemia. All these points would be finally translated into a reduction in the elapsed time between event onset and decision making by the physicians, leading to a significant reduction of the social impact of the disease and its associated economic costs.
A clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based technologies, VaxWave®, a replication-deficient viral vector, and TheraT®, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both, VaxWave® and TheraT®, are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA’s “off-the-shelf” viral vectors target dendritic cells in vivo to activate the immune system.
HOOKIPA has successfully completed a Phase 1 trial of a VaxWave®-based prophylactic vaccine to protect against cytomegalovirus infection and has started dosing patients in a Phase 2 trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens.
TheraT® and VaxWave® are not approved anywhere globally and their safety and efficacy have not been established.
A UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. Unlike IgG, IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours. IgE antibodies bind to their cognate receptors around 10,000 times tighter than IgG and this makes it an anticipatory receptor ideal for allowing macrophages, monocytes, basophils, mast cells and other immune effector cells to seek and destroy cancer cells.
Pre-clinical in vivo Proof of Concept has been obtained with two different IgE antibodies showing significantly greater efficacy versus IgG comparators in a variety of rodent cancer models. IGEM's pipeline comprises of IgE antibodies against folate receptor alpha, HER2 and CSPG-4. IGEM has an exclusive option to in-license IGEM-F, an anti-folate receptor alpha IgE currently in a phase I trial in ovarian cancer patients. This trial is being conducted by Cancer Research UK who co-own the asset with King’s College London. This is the world's first IgE antibody to enter the clinic.
A decentralized research organization (DRO) for staking and monetizing open science. IKU changes the status quo with decentralized contracts by distributing the risk, cost, and ownership of bio r&d, while simultaneously capturing the commercial value of relevant data via blockchain-based licensing. All participants (nodes) are economically aligned to build a progressively better intelligence. IKU's mission is to tear down walled gardens, eliminate research secrecy, and accelerate bio-innovation.
Proposed projects will satisfy 100x key value experiment criteria, a strategy vetted with Stanford SPARK Translational Research Program, to exponentially speed up the cycle in which actionable bio-information emerges for investors, scientists, and most importantly human longevity. The criteria being i) 100x efficiency when compared to the current market, ii) direct to Phase II/III human trial, iii) costs less than $3M, iv) biomarker established and v) support from trusted institution(s).
Current DRO pipeline includes neurodegeneration (alz.iku.network), antimicrobial resistance (www.antibx.com), and HPV.
IKU’s first project, the NeuroDRO, aims to deliver a breakthrough - plasmalogen supplementation - addressing neurodegeneration with research supported by University of Pennsylvania, Alzheimer’s Association, Duke University, and the NIH. The plasmalogen hypothesis was uncovered by emerging technology: non-targeted metabolomics using ultra-high-resolution mass spectrometry, capable of generating 100x more data points than traditional systems. This will be the first decentralized offering of its kind where anyone can have skin in the game.
Imcyse develops active targeted immunotherapies to treat and prevent severe chronic diseases caused by disruptions of the immune system. The company’s unique active immunotherapy technology platform allows it to destroy locally the immune cells involved in the destruction of the diseased organ. This platform is based on the administration of Imotopes™, which are specific modified peptides, allowing for the generation of a new type of T-cell, called cytolytic CD4. Imcyse’s approach, sustained over time, helps to prevent and treat diseases with no current therapeutic alternative and to cure the patient without impairing immune defenses. The company has established proof of concept and has completed its first clinical trial in type 1 diabetes in seven European countries. Results will be announced in September 2019. Other projects, which address multiple sclerosis, rheumatoid arthritis and neuromyelitis optica, are at preclinical and proof-of-concept research stages, respectively. Founded in 2010, Imcyse is a spin-off from the KU Leuven university, Belgium. The company is based near the Belgian city of Liège. It is managed by a group of former pharmaceutical industry executives.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.
A commercial pharmaceutical company focused on the discovery, development and subsequent commercialization of novel, first-in-class drugs for the treatment of cancer and other major diseases. Our lead drug candidate, Xpovio, as an oral agent in cancer indications with significant unmet clinical need, was approved by the FDA in June 2019 For the treatment of refractory Multiple Myeloma. We are also advancing the clinical development of Xpovio in Diffuse Large B-Cell Lymphoma and multiple solid tumor indications. To date, Xpovio has been administered to nearly 3,000 patients, some chronically for over two years. We also have a non-oncology program including two other SINE compounds, verdinexor and eltanexor. Verdinexor has strong anti-inflammatory and neuroprotective properties and is being developed for the treatment of autoimmune and inflammatory indications (including viral infections) with promising pre-clinical results in Systemic Lupus Erythematosus (SLE). Furthermore, verdinexor has completed a phase 1 study in healthy volunteers where it was found to be generally safe and well tolerated at pharmacologically relevant doses. Eltanexor is focused on autoimmune indications such as irritable bowel disease, with promising preclinical data.
Issue: Cancer is still one of the leading causes of death in the Western world, and metastasis—the spread of cancer to distant sites— and drug resistance represent the most critical attribute for therapy failure. Infiltrating distant tissue, evading immune defences, adapting to supportive niches, surviving as latent tumour-initiating seeds are key factors in the process of metastasis. Solution: Development of safe, efficacious, small molecule drugs that are affordable and based on the understanding of the biology of the innate immunity, metastasis and drug resistance.
A Swiss listed biotech company with three locations in Schlieren (Switzerland), Bilthoven (The Netherlands) and Burlington , MA (USA). Kuros Biosciences AG focuses on the development and commercialization of innovative products for bone repair and regeneration. The two key products are (1) MagnetOs, a marketed synthetic bone graft substitute with a unique surface topography, and (2)KUR-113. a novel orthobiologics candidate for use in spinal fusion scheduled to enter Phase II development in the second half of 2019. MagnetOs has a patent-protected surface topography that was shown to promote and direct bone formation. MagnetOs is CE-marked and 510k cleared and avisalable in two formulations( granules and putty). Product launch was in June 2018 in the US and in the UK.
KUR 113 is an innovative growth factor. Kuros is currently preparing for a Phase II study in spinal fusion. The technology is de-risked with two Phasse II programs completed in trauma indications (400 patients).
Life Length provides the world’s most advanced and accurate services in telomere and telomerase measurement and diagnostics for clinical usage. Life Length is Spain's most highly accredited laboratory and the only lab holding U.S. CLIA and ISO 15189 accreditation.
Our proprietary technology, Telomere Analysis Technology (TAT®), uniquely measures telomeres at the chromosomal level, providing the crucial measure for cell senescence, aging and age-related diseases.
Life Length offers its innovative diagnostic assays in a variety of fields ranging from contract services for pharma, nutraceutical, animal health clients and academic institutions for in vitro / in vivo studies for any molecule, compound or extract, stem cell characterization, investigating age-related diseases among many applications. Additionally, the TAT is used by leading physicians in preventive and personalized medicine for monitoring and evaluating aging and health status and therapy effectiveness. As an independent predictive biomarker for many diseases, Life Length’s telomere testing supports clinical decision making in early detection and risk stratification.
The Company has developed applications for its assays in cancer screening, diagnostis and prognosis and is currently finalizing the regulatory approvals to launch its services for improved prostate cancer screening with its patent-pending assay ProsTAV following three years of clinical trials; with assays for lung cancer and leukemia in development.
The above combined with our proprietary high-end technologies and accreditations make Life Length the world-leader in telomere diagnostics and measurements serving clients in more than 35 countries.
LimmaTech Biologics AG applies its proprietary CustomGlycan Platform to develop novel therapeutic biologics like monoclonal antibodies with tailored and homogenous glycosylation for maximal and novel effector functions. The platform is applicable to all protein formats and carries the potential to be a game changer in robustness, speed, and cost-efficiency of biologics production. It serves the need for cheaper, reproducible glycosylated biologics production in all indications.
LS CancerDiag has developed DiagMMR®, a novel predictive diagnostic test to detect the most common inherited cancer predisposition in the world, Lynch syndrome. Unlike the current array of tests, DiagMMR® provides easily interpretable and highly accurate results even before the cancer develops, enabling preventive and personalized care.
Lynch syndrome (previously known as hereditary non-polyposis colorectal cancer; HNPCC) is the most common hereditary cancer syndrome in the world and the affected individuals have an over 80% lifetime risk of developing cancer. The threshold for testing is very high due to the costs, ambiguity and low awareness of Lynch syndrome diagnostics. As a result, only 5% of affected people are diagnosed and the care remains largely reactive.
We want to become the global standard test for detecting Lynch Syndrome. By using our breakthrough functional test to detect Lynch Syndrome, we can help prevent cancer development through early and reliable diagnosis, enabling personalized care saving and improving millions of lives.
Macrophage Pharma is developing a novel class of small molecule therapeutics which modulate macrophage plasticity and function treat human disease. We leverage our proprietary Esterase Motif Technology™ (ESM™) platform. ESM™ to deliver small molecule inhibitors of key intracellular targets in a highly selective manner to, monocytes, macrophages and dendritic cells. We are progressing our lead molecules to the clinic, initially utilising ESM™ to deliver inhibitors to tumour associated macrophages and tolerogenic dendritic cells in the tumour microenvironment as cancer therapies. Macrophage involvement in a broad range of diseases means selective targeting with ESM™ also holds great promise in the treatment of inflammation, fibrosis and metabolic diseases.
The company’s management team has track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of our unique approach in immunotherapy.
Marinomed Biotech AG [VIE: MARI] [ISIN: ATMARINOMED6]
A biopharmaceutical company. It specializes in the development of innovative products based on patent protected technology platforms in the field of respiratory and ophthalmic diseases.
Marinomed has developed two platforms to date: the Marinosolv® technology platform and the Carragelose® platform.
The Marinosolv® technology platform enhances the efficacy of hardly soluble compounds. This innovative technology has the potential to sustainably change a number of therapies for allergies and auto-immune diseases. The flagship product Budesolv has recently been tested successfully in a pivotal Phase III approval study.
The Carragelose® platform is already used in six different products to treat viral infections of the respiratory tract, which are sold globally via the company’s partners.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells therapies, we believe that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase 2 clinical trials. https://www.markertherapeutics.com/
MEDINCELL [EPA: MEDCL]
A clinical stage pharmaceutical company developing long-acting injectables based on BEPO®, its game-changing technology platform enabling controlled, localized and sustained drug delivery. Independently and in partnership with other pharma or NGOs MedinCell develop a portfolio of best-in-class medicines incorporating additional benefits related to therapeutic compliance, targeted action and ease of use.
BEPO® physicochemical properties make it an ideal vehicle for a broad variety of compounds such as peptides, proteins and small molecules. BEPO® applications cover a wide range of unmet medical needs in neurology, cardiology, urology, gastroenterology, oncology, metabolic and immune diseases, pain management, and inflammation. In many situations, such as life cycle management, we can develop multiple duration prototypes to provide partners with greater strategic flexibility and competitive advantage.
MedinCell is dedicated to delivering innovative medical treatments to all global markets, mature and emerging alike. Via its active Global Health strategy, MedinCell aims to engage like-minded stakeholders where we can make a difference.
MedinCell is based in Montpellier, France, and employs more than 130 people representing over 25 different nationalities.
Metys Pharmaceuticals AG is developing MP-101 for the prevention and treatment of sensory symptoms of peripheral neuropathy. No therapy is indicated to treat or prevent chemotherapy-induced symptoms of peripheral neuropathy; these lead to premature interruption of cancer therapy and linger to reduce patients' quality of life and increase health care costs.
We seek Series A investors to finance the Phase 2 clinical trial of MP-101 in this indication. Our development plans have been discussed and agreed with FDA in a face-to-face pre-IND meeting in February this year. MP-101 is an orally active allosteric modulator of spinal and brain glutamate signalling. It is a patent-pending non-racemic mixture of the dimiracetam enantiomers. Metys Pharmaceuticals AG holds exclusive world-wide rights to the existing IND of racemic dimiracetam from two prior independent development efforts, and will use these data to support - without prior clinical or toxicological bridging data - the Phase 2 trial of MP-101.
Metys Pharmaceuticals AG is privately-held Swiss corporation, financed by private seed investors.
Omnix Medical is a pre-clinical company developing an arsenal of novel antibiotic-agents targeting Multi-Drug-Resistant bacteria. Our technology is inspired by the innate immune system of insects, employing a strategy that has been proven very efficient for 250 million years. Insects combat pathogenic bacteria using a unique family of Antimicrobial-Peptides that physically damage bacterial membranes with no toxic effects. The rapid-bactericidal Mechanism of Action employed by these peptides is active regardless of any existing antibiotic-resistance. Omnix's proprietary technology utilizes biochemical engineering to enable the synthesis of soluble, stable, safe and highly-potent Antimicrobial-Peptides. Our unique patented technology allows for a vast array of peptides to be designed for further therapeutic applications. The company’s lead molecule, OMN6, targets Superbugs. Omnix is focused on Gram(-) Multi-Drug-Resistant pathogens, the ESKAPE bacteria: K. pneumonia spp, A. baumannii, P. aeruginosa and Enterobacter spp. These bacteria are the most serious and urgent threats to public-health while the drugs intended to fight them become ineffective. High mortality-rates and limited therapeutic solutions make it an immediate unmet need. Omnix medical’s molecules are developed for the treatment of life-threatening hospital-acquired infections via systemic IV-administration. Omnix technology will save lives of millions suffering from infections involving antibiotic-resistant bacteria.
Omnix Medical was founded in 2015, and now Omnix team boasts 8 employees advancing R&D and directing studies with top-tier CROs.
Our patented platform technology offers a pipeline of peptides at various stages of development.
Omnix has raised funds from private/public investors in addition to Israeli-government grants.
OMN6 demonstrates high efficacy and presented a significant reduction in blood and lung bacterial-burden, in animal models. OMN6 presents a favorable PK/PD profile and has been designated QIDP by the FDA.
Omnix Medical technology can tilt the odds in the battle against Antimicrobial Resistance.
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid addiction and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129.
Our drug delivery technologies improve pharmaceuticals
Orexo develops improved products by combining well-known and well-documented substances with in-house innovative drug delivery technologies.
Developed 4 products approved worldwide
Orexo has developed four products from concept to patient. The products have been approved in multiple markets and helped patients benefit from improved drugs worldwide.
Strategic focus on product expansion
One of Orexo’s objectives for long-term growth is to broaden the US commercial platform, by M&A transactions, to leverage scale and expand sales.
Key market characterized by strong growth
In the US the #opioidcrisis is accelerating and in 2017 70,200 Americans died of an overdose, mainly caused by use of opioids. There is a great need for treatment and the buprenorphine/naloxone market grew by more than 14 percent in 2018.
Embracing all aspects of opioid addiction
Orexo’s pipeline contains development projects with a primary therapeutic focus around opioid addiction in all phases, from prevention to treatment.
A public clinical stage biopharmaceutical company listed on the Madrid stock exchange and a European leader in the development of epigenetics-based therapies. Oryzon has programs in clinical phase: CNS - Vafidemstat (ORY-2001), a dual LSD1-MAOB inhibitor, currently in three Phase IIA: • "ETHERAL": in mild to moderate AD • "REIMAGINE": aggression in adult population with Alzheimer’s Disease (AD), Adult attention deficit hyperactivity disorder (ADHD), Borderline Personality Disorder (BPD), and Autism Spectrum Disorder (ASD) • "SATEEN": in relapse-remitting and secondary progressive forms of MS. Oncology – Iadademstat (ORY-1001), a selective LSD1 inhibitor, currently in two Phase IIA: • "ALICE": in AML • "CLEPSIDRA": in SCLC A third epigenetic compound (ORY-3001), also against LSD1, has completed the preclinical development, for a yet undisclosed non-oncological indication. https://www.oryzon.com/
PDC*line Pharma SA
Founded in 2014 as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a Belgian-French clinical-stage biotech company that develops an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of plasmacytoid dendritic cells (PDC*line). PDC*line is much more potent than conventional Dendritic Cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can be applied to any type of cancer. Following a first-in-human phase I feasibility study in melanoma, PDC*line Pharma focuses on the development of PDC*lung01, a candidate for non-small-cell lung cancer (NSCLC) and neoantigens (PDC*Neo). The company has a staff of 20 people, with an experienced management team. The company has so far raised €17M ($19.3M) including €7.6M ($8.6M) in equity and loans from Belgian investors (MeusInvest, Innodem3, InvestSud and SFPI) and several business angels, in addition to €9.3M ($10.5M) of non-dilutive funding (including grants from the Walloon region, Belgium, French entities and the European Commission). In March 2019, the company granted an exclusive license to LG Chem Life Sciences Company in South Korea and an exclusive option in other Asian countries, for the development and commercialization of the PDC*lung01 cancer vaccine for lung cancer. The total deal value is €108M ($123M) plus tiered royalties on net sales in Asia.
Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma’s therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease.
Over the past 30 years and the first development of biologics, 30 therapeutic enzymes have been approved by EMA and FDA (1/4 of all approved biologics). Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). However, existing therapeutic enzymes exhibit both efficacy issues (lack of systemic stability, low residence time) and toxicity issues (up to 80% anti-drug reactions, immunogenicity).
Our platform technology has proved successful in addressing both these issues for non-therapeutic enzymes (see related company INOFEA AG). https://www.perseo-pharma.com/
Our vision is to save kidneys and prevent pain in children and adults with cystinuria. This genetic, orphan condition causes kidneys to leak amino acids - these crystalise, blocking urine flow.
We are a start-up biopharma company developing a novel, patented product to prevent crystal build-up in people with custinuria. Our product is a patented small molecule with a unique mechanism of action and robust preclinical data. This is a very underserved market and we are projecting peak sales of $450M.
Our experienced team has established orphan status and a clear development pathway with US and EU regulators and we have opened our Series A raise to get us to Phase 1 ready.
Phi Pharma SA is a private Swiss-based biotech company founded by well-known figures of the Swiss Biotech industry. It specializes in the development of drug conjugates with a first focus on liquid tumors.
Phi Pharma technology allows the development of a powerful new class of peptide drug conjugates which have the potential to overcome the limitations of Antibody Drug Conjugates.
Phi Pharma’s technology is based on the groundbreaking discovery of HIV using TAT peptide to penetrate white blood cells to deliver its deadly cargo. Naturally occurring TAT peptide has a very short half-life in blood as it is being instantly degraded by respective enzymes.
By super-computer assisted modelling Phi Pharma was able to identify, synthesize and patent protect “semi-synthetic” TAT derived peptide with dramatically improved stability and affinity, hence targeting properties.
After extensive in-vitro work showing the expected biological activity, Phi Pharma is completing the pre-clinical development of the lead compounds to move into IND and the implementation of a first in human PoC phase 1/2a clinical trial.
A leading global innovative anaesthesia company, expanding in paediatric pharmaceuticals.
Primex brings a broad portfolio of anaesthesia products helping patients undergo a wide range of medical procedures, including a novel, oral solution for paediatric sedation now approved in several markets in the European Union.
Primex Pharmaceuticals will continue to identify and bring to the market new medications that complete the Triad of Anaesthesia.
Primex Pharmaceuticals is headquartered in Switzerland.
A biotech company with an asset, RV001, in clinical phase 2b. RV001 is an antigen mediated immuno-therapy that triggers the immune system to target and destroy metastatic cells, and metastatic cells only, on the basis of their unique over-expression of the protein RhoC, a protein that lends to metastatic cells their lethal ability to migrate and infiltrate other tissues. In its phase 2b (ca. 175 patients) trial, RV001 is being studied for its ability to prevent cancer recurrence (measured as PSA rise) after radical prostatectomy in prostate cancer. But the RhoC targeting principle is probably generally applicable to other metastatic cancers too. As such, RhoVac is looking for a licensee or an acquirer among large oncology focused pharmas after the phase 2b study. Phase 2b results will be at hand mid 2021. We might consider an option deal prior to that.
A near clinical Swiss Biotech Company developing a unique approach to bring personalized medicine to patients with Autism Spectrum Disorder (ASD). Today, patients with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need. In its Geneva and Barcelona units, STALICLA has assembled world class teams of experienced drug developers and computational biologists. The company is recognized as a disruptive player, using its systems biology DEPI platform to identify subgroups of patients with ASD and candidate repurposed and rescued drugs. Patients are then characterized through biomarker preclinical and clinical investigations. This translates into a derisked drug development process bringing the vision of ASD personalized medicine to reality. STALICLA’s first therapeutic package - STP1 - addresses a distinct sub-group of ASD patients estimated to 1.5-2M people in the EU and North America. To support STP1 development and create strong value for all stakeholders, STALICLA has developed a network of top tier research and clinical partners and established IP as a strategic priority. STALICLA is currently applying its DEPI discovery model to advance new pipelines for additional groups of patients. Applicability of the DEPI platform goes beyond ASD and has potential for drug discovery in other complex ill-defined diseases.
Q1 2019 – Three new modules have been added to the DEPI v.III platform, exponentially increasing its capacities for single and combination drug repositioning and for identification of clinical trial stage drug high responder patients in complex neurodisorders.
Themis is developing immune-modulation therapies for infectious diseases and cancer. The Company’s lead asset maintains its front-runner position world-wide and is currently in final preparations for a pivotal global Phase 3 clinical trial. The Company has built a sophisticated and versatile technology platform, and a robust commercial-scale manufacturing process for the discovery, development and production of vaccines as well as other immune system activation approaches, based on the advanced understanding of immune system mechanisms. Initially focused on preventing infectious diseases, the Company has demonstrated the potential of its versatile platform through the rapid progression into Phase 3 clinical development for a vaccine against Chikungunya, a debilitating disease with global outbreak potential. Themis launched an immunotherapy franchise in the second half of 2018 to further exploit the potential of its platform in oncolytic virotherapy and is rapidly moving the lead asset into a Phase 1 study in 2019 to treat gastrointestinal cancer. Funded to date by high profile EU- and US-based VCs, Themis has also gained prestigious non-dilutive funding for emerging infectious disease indications, including two partnerships with the Coalition for Epidemic Preparedness Innovations (CEPI). The Company will apply its platform and manufacturing capabilities to diseases with high market potential both alone and for its partners.
A spin-off of the ETH Zurich. The company was founded in 2017 by ETH scientists and experienced executives from the pharmaceutical industry. It has since raised almost $12 million to beat drug resistance in cancer therapy.
TOLREMO uses a proprietary drug resistance screening platform to identify novel drug targets and develop resistance-preventing small molecules. The company's compounds can be combined with existing cancer drugs to prevent resistance development and increase patient survival.
TOPADUR Pharma AG is a biopharmaceutical start-up company based at the Bio-Technopark in Schlieren-Zürich, Switzerland. The company was established in April 2015 and is a successor of TOPADUR GmbH founded in 2009. It was qualified as SME by EMA on May 22, 2017. TOPADUR is also a CTI-certified company. The company focusses on research and development for diseases with highly unmet medical needs. Topadur invented a new type of drugs, small molecular weight drugs with dual mode of action resulting in a rich pipeline of innovative drug candidates to enable healing of chronic wounds, avoid scar formations after burn wounds, treat mayor eye and aging diseases and improve patients quality of live. The leading development drug for is foreseen to enter this year the clinical development phase in diabetic fott ulcer and in a rare ulcer indication.
•Topadur’s leading drug, TOP-N53 enables the healing of chronic wounds such as diabetic foot ulcers (DFU) and orphan ulcera. It is entering clinical trials end of 2019. •TOP-N53 has the potential for a breakthrough medication in a disease with very high unmet medical need, saving more than one million foot amputations every year and prevent patients from dying. •TOP-V122 and TOP-T5 are drug candidates in pre-clinical stage, predicted to increase ocular microcirculation and neuroprotection. It addresses glaucoma conditions and has the potential to become a breakthrough drug preventing blindness in several ophthalmic diseases. •TOP-N44 is a drug candidate in preclinical development, which we expect based on preclinical data to inhibit scar formation after burn wounds. •TOP-M119 is a very potent hair growth promoter. Since loss of sensory hair cells in the inner ear is the main reason for age dependent hearing loss it is foreseen to evaluate the potential of this drug candidate in relevant animal models.
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients.
We will advance a range of conjugates, unlimited by indication, using our own discovery capabilities and by solving development challenges for partners with both antibody and chemical assets.
The expertise of UGA Biopharma is the development of biologics and biosimilars. This high speed contract development involves all the necessary steps from cell line development and bioprocess development to the development of purification processes and analytics. Furthermore, First CHOice® high-performance cell culture media and feeds are supplied in order to optimize the quality and product concentration of biologics and biosimilars. In addition, UGA Biopharma offers to customers ready-to-use biosimilar cell lines. The company supplies its customers in Germany and abroad from its headquarters in Hennigsdorf and already has several clients with UGA products in clinical trials or who have already received a market approval.
A biopharmaceutical company located in Basel, Switzerland, fully operating since 2018. It was founded after many years of research for superior results of novel therapies for the local and efficacious delivery of therapeutic proteins to accelerate tissue regeneration and improve maintenance. The company's VERSagile mRNA technology platform rapidly revealed various options for a broad range of therapeutic applications, thus providing multiple new drug development opportunities for both Versameb as well as potential partners. https://versameb.com/
Zmed Laser Ltd.
Following the success of Alma Laser, Dr. Ziv Karni and his team are offering a full line of unique and un-matched innovative solutions based on minimally invasive laser technologies for Surgical & Professional Aesthetic Applications. Zmed solutions are setting a new gold standard with maximum results and patients’ comfort, for out-patient/in-clinic procedures in Professional Aesthetics, Gynecology, Proctology, Plastic Surgery and more.